Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea · Delayed Price · Currency is KRW 1,683,000
-12,000 (-0.71%)
Jan 2, 2026, 3:30 PM KST
Samsung Biologics Revenue
Samsung Biologics had revenue of 1.66T KRW in the quarter ending September 30, 2025, with 39.86% growth. This brings the company's revenue in the last twelve months to 5.50T, up 26.13% year-over-year. In the year 2024, Samsung Biologics had annual revenue of 4.55T with 23.08% growth.
Revenue (ttm)
5.50T
Revenue Growth
+26.13%
P/S Ratio
14.25
Revenue / Employee
1.15B
Employees
4,770
Market Cap
78.46T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.55T | 852.73B | 23.08% |
| Dec 31, 2023 | 3.69T | 693.29B | 23.10% |
| Dec 31, 2022 | 3.00T | 1.43T | 91.41% |
| Dec 31, 2021 | 1.57T | 403.23B | 34.62% |
| Dec 31, 2020 | 1.16T | 463.19B | 66.02% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |
| ABL Bio | 88.44B |
Samsung Biologics News
- 11 days ago - Samsung Biologics Expands U.S. Presence with $280M Acquisition - GuruFocus
- 11 days ago - Samsung Biologics acquires Human Genome Sciences from GSK - Seeking Alpha
- 11 days ago - Samsung Biologics To Acquire GSK's Rockville Facility For US$280 Mln - Nasdaq
- 11 days ago - Samsung Biologics to Acquire Human Genome Sciences from GSK - GuruFocus
- 2 months ago - Samsung BioLogics Co Ltd (XKRX:207940) Q3 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
- 3 months ago - Korean Stock Market Declines Amid Trade Uncertainty; Samsung Biologics (SSNLF) Drops - GuruFocus
- 3 months ago - Asian drug market stocks slides: Trump’s 100% pharmaceutical tariffs shake market; broader impact on Japan likely minimal - The Times of India